Rocky Point Aquaculture in southeast Queensland experienced a disease outbreak in cage-reared giant grouper (Epinephelus lanceolatus) in late summer and autumn 2018 resulting is severe losses caused by a Betanodavirus. Following a request from the farm owner, Serena Zipf in July 2018, Dr Andrew Barnes from The University of Queensland, designed and built a recombinant protein subunit vaccine against the Betanodavirus and supplied the construct and production outline to Tréidlia BioVet Pty Ltd (Sydney) for manufacture in September 2018. Under direction from Dr Matt Landos and Dr James Fensham (Future Fisheries Veterinary Services) and with permission from Dr Richard Knuckey (General Manager, The Company One), juvenile grouper were vaccinated under a research permit from the Australian Pesticides and Veterinary Medicines Authority (APVMA) at The Company One (TCO) Cairns hatchery in October 2018, and shipped for grow-out at Rocky Point Aquaculture in December 2018, less than 6 months after concept discussion. Vaccination coincided with a reduction in the severity of outbreaks and from mid-2019 to 2022 the farm was free from nodavirus outbreaks. In summer 2022, a persistent low-level  outbreak was recorded at the farm in vaccinated fish, although again well below the mortality levels of the 2018 outbreak. In controlled laboratory challenge studies by Dr Kelly Condon at James Cook University, the vaccine has been shown to be >90% effective. Vaccinated juveniles have also been purchased by Noosa Ecomarine and the vaccine has also coincided with substantially reduced mortalities by nodavirus in their recirculating aquaculture facility.